Shubh Gupta, PhD

Co-Founder, CEO and Chief Scientific Officer

Immumem Therapeutics

Richmond, California United States

About Me

Immumem Therapeutics' leadership is spearheaded by Dr. Shubh Gupta, who serves as the Co-founder, CEO and Chief Scientific Officer (CSO). With a PhD in Translational Biology and Molecular Medicine, Dr. Gupta is an accomplished scientist with a robust background in CAR T and NK cell immunotherapy. His expertise spans research in hematological and solid tumors, gene editing, lab operations, and leading multi-disciplinary teams. Dr. Gupta has held previous roles at Caribou Biosciences and Fate Therapeutics, and has demonstrated significant achievements in pipeline product development, clinical trial advancement, and collaborative research efforts. Under his leadership, Immumem Therapeutics is poised for innovative advancements in iPSC-derived cell therapies targeting solid tumors.

You have not backed any projects. Lets change that!
Discover Projects

No project created yet. Lets change that!
Discover Projects

No comments on any project yet. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No project reviewed yet. Lets change that!
Discover Projects

Important Disclosure: MedStartr.com is a website owned and operated by MedStartr, Inc., which is not a broker-dealer, funding portal or investment advisor; and neither the website nor MedStartr, Inc. participate in the offer or sale of securities. All securities related activity is conducted through Young America Capital, LLC, a registered broker-dealer and member of FINRA/SIPC. No communication, through this website, email or in any other medium, should be construed as a recommendation for any securities offering.